Radiopharm Theranostics (ASX:RAD) Beta: 0.5769 (As of Jun. 24, 2026)


What is Radiopharm Theranostics Beta?

Radiopharm Theranostics ASX:RAD -5.00% Beta is 0.5769 as of Jun. 24, 2026. The stock has 5 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-24), Radiopharm Theranostics's Beta is 0.5769.

Radiopharm Theranostics  (ASX:RAD) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)

Radiopharm Theranostics Beta Related Terms

Radiopharm Theranostics Beta Historical Data

* Premium members only.

The historical data trend for Radiopharm Theranostics's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Radiopharm Theranostics Beta Chart

Radiopharm Theranostics Annual Data
Trend Jun22 Jun23 Jun24 Jun25
Beta
0.00 0.00 0.00 0.75

Radiopharm Theranostics Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
Beta Get a 7-Day Free Trial 0.00 0.00 0.00 1.01 0.75

ASX:RAD vs VRTX, REGN, ALNY: Beta Comparison

For the Biotechnology subindustry, Radiopharm Theranostics's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Radiopharm Theranostics Beta vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Radiopharm Theranostics's Beta distribution charts can be found below:

* The bar in red indicates where Radiopharm Theranostics's Beta falls into.


Radiopharm Theranostics Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 0.5769 mean?
Radiopharm Theranostics (ASX:RAD) has a Beta of 0.5769 as of Jun. 24, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Radiopharm Theranostics and its competitors.
Is Radiopharm Theranostics' Beta too high?
Radiopharm Theranostics' current Beta is 0.5769.
How does Radiopharm Theranostics' Beta compare to VRTX and REGN?
Radiopharm Theranostics' Beta of 0.5769 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Biotechnology company?
A good Beta depends on the Biotechnology industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Radiopharm Theranostics and its competitors. Radiopharm Theranostics's current Beta is 0.5769. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Radiopharm Theranostics stock overvalued right now?
Radiopharm Theranostics (ASX:RAD) has a current Beta of 0.5769. The current Beta is 0.5769. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Radiopharm Theranostics (ASX:RAD), the current Beta is 0.5769 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Radiopharm Theranostics Business Description

Other Exchanges RADX:USA
Address 62 Lygon Street, Suite 1, Level 3, Carlton South, Melbourne, VIC, AUS, 3053
Radiopharm Theranostics Ltd is an Australian-based clinical-stage radiotherapeutics company targeting cancer. The company has a pipeline of approximately four licensed platform technologies, with diagnostic and therapeutic applications at both the pre-clinical and clinical stages of development. The company is engaged in research, development, and commercialization of health technologies.